South Korea’s Gangwon province is building a biohealth ecosystem to expand globally, with a focus on research and development, real-world demonstrations, commercialisation, and overseas expansion. The province accounts for 15.08% of South Korea’s medical device exports and has an established medical device industry.
Gangwon Province is taking steps to bolster its economy by backing local businesses, drawing in outside funding, and generating employment opportunities. Central to this strategy is positioning the region as a leading center for biohealth innovation.
The event focused on strengthening ties between South Korean healthcare firms and international medical research sites. Yoon Wan-tae, who leads the Future Business Division at Gangwon Technopark, shared updates on the Special Zone’s accomplishments and future direction. Meanwhile, Rha Koon-ho from NAVER Healthcare Lab delivered a keynote on how generative AI is reshaping digital healthcare.
Read Also: Fullerton Health Launches Proactive Wellness Center in Singapore
Global experts at the forum examined both the potential and obstacles of bringing healthcare innovations to international markets. Ain Aaviksoo, CEO of Estonia’s Mentastic, highlighted advancements in regulatory frameworks and Estonia’s shift toward digital health solutions. Mila Hoang, representing Vietnam’s SVF, analyzed trends in Southeast Asia’s healthcare sector and strategies for adapting products to local needs.
Gangwon already boasts a thriving medical device sector, with over 20 specialized firms and research institutions. The Wonju region alone hosts more than 200 companies and organizations focused on medical technology. The Wonju Medical Industry Technovalley assists businesses through technology sharing, collaborative research, and access to advanced equipment and testing spaces.
Among the province’s cutting-edge healthcare firms is GeoMex Soft Co., Ltd., which created AI-PAM—a system using AI-powered video analysis and smart surveillance cameras to track patients and prevent falls. Another key player, MEZOO Co., Ltd., specializes in portable remote patient monitoring and has earned regulatory approvals in nine countries.
Read Also: Hong Kong Shoppers Set to Spend One-Third Abroad
MEZOO’s HiCardi system features a compact sensor patch worn on a patient’s chest, paired with software that monitors multiple individuals simultaneously. It continuously tracks vital signs like ECG readings, breathing patterns, and body temperature, making it ideal for hospitalized patients and those managing chronic illnesses. The device has met regulatory standards in the U.S. (FDA 510(k)), Europe (CE mark), and Japan (PMDA), with over 16 approvals across nine nations.
Beyond medical devices, Gangwon is advancing in antibody research and biotechnology. The Hongcheon National Antibody Cluster, for instance, hosts 17 biotech firms focused on antibody-based therapies, vaccines, and experimental drugs. The cluster offers research infrastructure, business support, and specialized training to support industry growth.
The province also held the Gangwon Bio Expo from 29 October to 1 November, bringing together 120 companies and institutions for exhibitions, business meetings, and forums. This event highlights Gangwon’s commitment to establishing itself as a global biohealth hub and expanding its presence in the international market. The expo showcased the province’s capabilities and attracted attention from around the world.
